Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBIT Margin: 2022-2025

Historic EBIT Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to 8.59%.

  • Arcutis Biotherapeutics' EBIT Margin rose 9588.00% to 8.59% in Q3 2025 from the same period last year, while for Sep 2025 it was -12.03%, marking a year-over-year increase of 11913.00%. This contributed to the annual value of -65.33% for FY2024, which is 33916.00% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' EBIT Margin stood at 8.59%, which was up 147.93% from -17.93% recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' EBIT Margin peaked at 3,407.40% during Q1 2022, and registered a low of -14,448.00% during Q3 2022.
  • Its 3-year average for EBIT Margin is -452.24%, with a median of -87.29% in 2024.
  • Data for Arcutis Biotherapeutics' EBIT Margin shows a peak YoY increase of 1,432,499bps (in 2023) and a maximum YoY decrease of 614,976bps (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Arcutis Biotherapeutics' EBIT Margin stood at -2,310.84% in 2022, then soared by 185,861bps to -452.23% in 2023, then soared by 44,154bps to -10.70% in 2024, then soared by 9,588bps to 8.59% in 2025.
  • Its EBIT Margin was 8.59% in Q3 2025, compared to -17.93% in Q2 2025 and -37.25% in Q1 2025.